Technology behind the pipeline
Seamless translation of big data Ai-analytics to in vitro and in vivo therapeutic validation
GENIMAPS® and GENISYST® technology integration facilitates Ai-driven target and drug identification, and direct therapeutic validation in vitro (2D and 3D), and in small and large animal models. This coupled workflow enables efficient and accelerated drug discovery and stringent efficacy validation.
Ex vivo/in vivo precision disease modeling
Translating Ai-driven big data analytics into precision ex vivo and in vivo disease models
Target identification
Ai-driven pattern recognition and hierarchical clustering platform to uncover indication- and tissue
Transcriptome based disease heterogeneity mapping
Cell subpopulation heterogeneity mapping based on bulk trancriptomics data.
Subpopulation-Enriched Genome-Wide association
Cell subpopulation heterogeneity mapping based on bulk genomics data.
Drug repositioning
Big data-driven multimodal molecular signature mapping to facilitate drug repositioning and accelera
Preclinical heterogeneity modelling
GENISYST implements complex disease heterogeneity patterns in vitro and in small/large in vivo model
Preclinical multiplexed target validation
